Beta-Blockers After Heart Attack – Rethinking Routine Use ?

MBBS
1

For decades, beta-blockers have been a cornerstone of therapy after myocardial infarction (MI). However, new evidence presented at the ESC Congress 2025 in Amsterdam is challenging this practice.

Recent large-scale trials such as REBOOT and REDUCE-AMI showed that in patients with preserved left ventricular ejection fraction (LVEF ≥ 50%), routine long-term beta-blocker use did not significantly reduce mortality or recurrent heart attacks.

This means the “one-size-fits-all” approach may no longer be justified. Instead, beta-blocker therapy should be individualized—still crucial for patients with heart failure, arrhythmias, or reduced EF, but perhaps unnecessary for all post-MI patients.

This shift marks an important step toward personalized cardiology, where treatment decisions are based on patient profiles and evolving evidence rather than tradition.

MBH/AB

1 Like
2

Very insightful . Evidence based medicine at its best . Evidence is reshaping long standing practices in cardiology . Moving from routine to personalized therapy is needed in the future of better patient care and outcomes .

3

This was needed in the world of cardiology!!

4

This is such an important update in cardiology :fire:. For years, beta-blockers were prescribed almost by default after MI, but now we’re seeing a shift from tradition → personalization.

It reminds us that:

:white_check_mark: Not every “gold standard” stays golden forever.

:white_check_mark: Evidence-based medicine is dynamic — what was lifesaving yesterday may need refining today.

:white_check_mark: Patients with reduced EF or arrhythmias still benefit greatly, but those with preserved EF might avoid unnecessary side effects like fatigue or bradycardia.

This evolution shows the true beauty of medicine: we keep questioning, learning, and tailoring care for better outcomes. Personalized cardiology is no longer the future — it’s here. :heart: